secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATAI Life Sciences N.V. (—)
CIK:        0001840904
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001140361-25-000708
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

atai appoints Srinivas Rao as sole CEO, Gerd Kochendoerfer as COO, promotes Kevin Craig to CMO and Glenn Short to CSO
--------------------------------------------------------------------------------

- Dr. Srinivas Rao becomes sole CEO effective Jan 1, 2025, after co-CEO transition.
- Gerd Kochendoerfer appointed COO effective Dec 3, 2024, from NFlection Therapeutics.
- Kevin Craig promoted to CMO leading VLS-01 and EMP-01 Phase 2 trials; Glenn Short named CSO.
- VLS-01 now screening patients; Phase 2b data for BPL-003 (Beckley Psytech) expected mid-2025.
- Dr. Rao receives $629,200 base salary, 55% bonus target, and option for 2.34M shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/0001140361-25-000708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840904/000114036125000708/ef20040004_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer